Mirum Pharmaceuticals (MIRM) traded lower on Thursday, April 23, 2026 (down about 3% to roughly $91.63 in the user-provided quote) without an obvious single catalyst such as an earnings release, an FDA decision, or a new clinical-data headline. With the company’s last major corporate update tied to its Q4/full-year 2025 results (February 25, 2026) and Bluejay acquisition completion earlier in 2026, the day’s weakness looks more like routine biotech volatility and profit-taking than a fundamentals reset. (ir.mirumpharma.com)

The next widely watched fundamental catalyst remains topline results from the VISTAS Phase 2b study of volixibat in primary sclerosing cholangitis (PSC), which Mirum has pointed to for release in the second quarter of 2026. With that readout approaching, the stock can swing on positioning changes even in the absence of fresh news. (fool.com)

Beyond trial timing, investors have been sensitive to supply/demand dynamics around Mirum shares following strategic activity. The company completed its Bluejay acquisition on January 23, 2026 and issued shares in connection with the transaction, which can contribute to intermittent selling pressure and rebalancing as new holders and legacy stakeholders adjust exposure. (sec.gov)

Traders will be focused on any update that narrows the timing and expectations for the VISTAS readout, along with broader pipeline milestones Mirum has highlighted as potentially “registrational” over the coming 18 months. Separately, investors will continue to watch for any additional SEC filings that could signal further changes in share availability or insider activity. (ir.mirumpharma.com)